Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
04-02-03 Lithium
Lithium preparations vary widely in bioavailability and should therefore be prescribed by brand name. Lithium carbonate 200mg ≡ lithium citrate 509mg.
Lithium preparations vary widely in bioavailability and should therefore be prescribed by brand name. Lithium carbonate 200mg ≡ lithium citrate 509mg.
| Lithium Carbonate Camcolit® |
|
Formulary
|
M/R tablets 400mg |
 LSCMMG: Shared care guideline |
|
| Lithium Carbonate Priadel® |
|
Formulary
|
M/R tablets 200mg, 400mg |
|
LSCMMG: Shared care guideline |
|
|
| Lithium Citrate Priadel® |
|
Formulary
|
Liquid 520mg/5mL |
|
LSCMMG: Shared care guideline |
|
|
Links
- LMMG SCG Lithium July 2019
- LMMG SCG Lithium July2019
- LSCMMG: Shared care guideline
- LSCMMG: Shared care guideline
- LSCMMG: Shared care guideline
- MHRA Drug SAfety Update April 2018: Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met
- MHRA Drug Safety Update April 2019: Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme
- MHRA Drug Safety Update April2018: Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met
- MHRA Drug Safety update Feb 2016 : Valproate and of risk of abnormal pregnancy outcomes: new communication materials
- MHRA Drug Safety Update Feb 2016: Valproate and of risk of abnormal pregnancy outcomes: new communication materials
- MHRA Drug Safety Update Sept 2018: Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers
- MHRA Drug Safety Update Sept 2018: Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers
- MHRA: Valproate use in men: as a precaution, men and their partners should use effective contraception
- MHRA: Valproate use in men: as a precaution, men and their partners should use effective contraception
- NICE CG103: Delirium: prevention, diagnosis and management
- NICE CG178 Psychosis and schizophrenia in adults: prevention and management
- NICE CG38: Bipolar disorder: Bipolar disorder: assessment and management
- UHMB Lithium therapy risk assessment form
- UHMB Lithium therapy risk assessment form
- UHMB lithium therpay risk assessment form